MDGL Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
431.3M
+18.4%
364.3M
+17.0%
311.3M
-3.0%
321.1M
+11.8%
287.3M
Cost of Revenue
0
0
-100.0%
26.8M
0
0
Gross Profit
431.3M
+18.4%
364.3M
+28.0%
284.5M
-11.4%
321.1M
+11.8%
287.3M
Operating Expenses
375.3M
-10.8%
420.6M
+11.5%
377.2M
-0.9%
380.7M
-5.1%
401.2M
R&D
71.8M
-21.3%
91.2M
-16.1%
108.7M
-6.5%
116.3M
-33.2%
174.0M
SG&A
265.7M
-8.2%
289.4M
+7.8%
268.5M
+11.9%
240.0M
+14.8%
209.1M
Operating Income
56.0M
+199.4%
-56308000
+39.3%
-92723000
-55.6%
-59609000
+47.7%
-113975000
EBITDA
56.4M
+200.8%
-55927000
+39.4%
-92337000
-55.9%
-59217000
+47.9%
-113617000
Net Income
55.4M
+195.7%
-57939000
+38.6%
-94391000
-61.1%
-58575000
+48.7%
-114190000
EPS (Basic)
$1.90
+195.5%
$-1.99
+38.8%
$-3.25
+72.8%
$-11.93
-197.5%
$-4.01
EPS (Diluted)
$1.83
+192.0%
$-1.99
+38.8%
$-3.25
+72.8%
$-11.93
-197.5%
$-4.01
Shares (Diluted)
30.3M
+4.0%
29.1M
+0.4%
29.0M
+491.1%
4.9M
-82.8%
28.5M
Madrigal Pharmaceuticals (MDGL) — Financials